Biosimilars in the French and Polish System: Chosen Aspects of Reimbursement and Access
Biosimilars in the French and Polish System: Chosen Aspects of Reimbursement and Access
About this item
Full title
Author / Creator
Publisher
Łódź: Wydawnictwo Uniwersytetu Łódzkiego
Journal title
Language
English
Formats
Publication information
Publisher
Łódź: Wydawnictwo Uniwersytetu Łódzkiego
Subjects
More information
Scope and Contents
Contents
The EU approved the first biosimilar drug in 2006. By 2017, the EU had authorized the highest number of biosimilars worldwide, acquiring considerable experience in their use and safety. In May 2019, the European Medicines Agency (EMA) search engine showed 54 authorized biosimilars. Biosimilars reduce public expenditure; however, the discussion abou...
Alternative Titles
Full title
Biosimilars in the French and Polish System: Chosen Aspects of Reimbursement and Access
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_ceeol_journals_877459
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_ceeol_journals_877459
Other Identifiers
ISSN
1508-2008,2082-6737
E-ISSN
2082-6737
DOI
10.18778/1508-2008.23.15
